Abstract
Breast cancer is the second leading cause of cancer death affecting women in the United States, with more than 180,000 new cases each year. Even with recent advances in breast cancer treatment, approximately one-half of breast cancer patients will eventually die of this disorder. The high mortality of breast cancer has focused attention on prevention and on identifying breast cancer precursors. Invasive breast cancer may develop gradually from specific microscopically defined precursor lesions. However, these lesions are relatively common and only a small proportion of the proposed precursor lesions appear to progress to invasive breast cancer, emphasizing that progression is nonobligatory. Identifying biologic and genetic abnormalities that herald progression to invasive breast cancer may enable us to intervene before progression occurs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Selected References
Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200–206.
Allred DC, O’Connell P, Fuqua SAW. Biomarkers in early breast neoplasia. J Cell Biochem 1993; 17G: 125–131.
Alpers CE, Wellings SF. The prevalence of carcinoma in situ in normal and cancer-associated breasts. Hum Pathol 1985; 16: 796–807.
Bartow SA, Pathak DR, Black WC, Key CR, Teaf SR. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer: a forensic autopsy study. Cancer 1987; 60: 2751–2760.
Bodian CA, Perzin KH, Lattes R, Hoffmann P, Abernathy TG. Prognostic signifi- cance of benign proliferative breast disease. Cancer 1993; 71: 3896–3907.
Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682–4689.
Carter CL, Corle DK, Micozzi MS, Schatzkin A, Taylor PR. A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol 1988; 128: 467–477.
Casey G. The BRCA 1 and BRCA2 breast cancer genes. Curr Opin Oncol 1997; 9: 88–93.
Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kipl protein: prognostic implications in primary breast cancer. Nat Med 1997; 3: 227 - 230.
Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 3: 146–151.
Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with prolif-erative breast disease and atypical hyperplasia. Cancer 1993; 71: 1258–1265.
Easton D, Ford D, Peto J. Inherited susceptibility to breast cancer. Cancer Sury 1993; 18: 95–113.
Frykbert ER, Masood S, Copeland EM, Bland KI. Ductal carcinoma in situ of the breast. Surg Gynec Obstet 1993; 177: 425–440.
Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hindau Rosenthal Foundation Award Lecture. Cancer Res 1988; 48: 246–253.
Hurlin PJ, Ayer DE, Grandori C, Eisenman RN. The Max transcription factor network: involvement of Mad in differentiation and an approach to identification of target genes. Cold Spring Harb Symp Quant Bio11994; 59: 109–116.
Kintanar EB, Raju U. Further delineation of patterns of atypical ductal hyperplasia (ADH): an analysis of ADH patterns associated with intraductal and invasive breast carcinoma. Mod Pathol 1991; 4: 12A.
Knudson AG. Hereditary cancer, oncogenes, and anti-oncogenes. Cancer Res 1985; 45: 1437–1443.
Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N. An association between the risk of cancer and mutations in the HRAS 1 minisatellite locus. N Engl J Med 1993; 329: 517–523.
Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351: 453–456.
London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992; 267: 941–944.
Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brcal, Brca2, Brcal/Brca2, Brcal/p53, and Brca2/p53 nullizygous embryos. Genes Dev 1997; 11: 1226–1241.
McDivitt RW, Stevens JA, Lee NC, Wingo PA, Rubin GL, Gersell D. Histologic types of benign breast disease and the risk for breast cancer. Cancer 1992; 69: 1408–1414.
NSABP Protocol P-1. A clinical trial to determine the worth of tamoxifen for preventing breast cancer. Pittsburgh, PA: National Surgical Adjuvant Breast and Bowel Project, 1992.
O’Connell P, Pekkel V, Fuqua SAW, Osborne CK, Allred DC. Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat 1994; 32: 5–12.
Osborne CK, Clark GM, Ravdin PM. Adjuvant systemic therapy of primary breast cancer. In: Harris JR, Lippman ME, Morrow M, Hellman S., eds. Diseases of the Breast. Philadelphia: Lippincott-Raven, 1996; pp. 487–547.
Osborne CK. Receptors. In: Harris JR, Hellman S, Henderson IC, Kinne DW, eds. Breast Diseases. Philadelphia: JB Lippincott, 1991; pp. 301–325.
Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997; 3: 222–225.
Powles TJ, Jones AL, Ashley SE, et al. The Royal Marsden Hospital Pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 1994; 31: 73–82.
Rutqvist LE, Cedermark B, Glas U, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991; 83: 1299–1306.
Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hyper-sensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997; 386: 804–810.
Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987; 316: 1289–1294.
Suzuki A, de la Pompa JL, Hakem R, et al. Bcra2 is required for embryonic cellular proliferation in the mouse. Genes Dev 1997; 11: 1242–1252.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Berardo, M.D., Allred, D.C., O’Connell, P. (1998). Breast Cancer. In: Jameson, J.L. (eds) Principles of Molecular Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-726-0_63
Download citation
DOI: https://doi.org/10.1007/978-1-59259-726-0_63
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-6272-3
Online ISBN: 978-1-59259-726-0
eBook Packages: Springer Book Archive